Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Olmesartan | hsa00020 | Citrate cycle (TCA cycle) | 3.41E-02 | 2 | P50213, O14521 | IDH3A, SDHD | More | | Olmesartan | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Olmesartan | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Olmesartan | hsa00071 | Fatty acid degradation | 4.66E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | Olmesartan | hsa00190 | Oxidative phosphorylation | 4.36E-03 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Olmesartan | hsa00220 | Arginine biosynthesis | 6.33E-04 | 3 | P15104, P05089, P49448 | GLUL, ARG1, GLUD2 | More | | Olmesartan | hsa00500 | Starch and sucrose metabolism | 1.27E-08 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Olmesartan | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | Olmesartan | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | Olmesartan | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Olmesartan | hsa00591 | Linoleic acid metabolism | 1.29E-03 | 1 | P11712 | CYP2C9 | More | | Olmesartan | hsa00730 | Thiamine metabolism | 5.65E-05 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Olmesartan | hsa00770 | Pantothenate and CoA biosynthesis | 2.26E-04 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | Olmesartan | hsa00910 | Nitrogen metabolism | 2.93E-02 | 2 | P22748, P49448 | CA4, GLUD2 | More | | Olmesartan | hsa00970 | Aminoacyl-tRNA biosynthesis | 1.69E-07 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | Olmesartan | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Olmesartan | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Olmesartan | hsa00983 | Drug metabolism - other enzymes | 2.22E-03 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | Olmesartan | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | Olmesartan | hsa01230 | Biosynthesis of amino acids | 3.91E-02 | 3 | P51854, Q99707, P50213 | TKTL1, MTR, IDH3A | More | | Olmesartan | hsa01240 | Biosynthesis of cofactors | 2.95E-02 | 2 | P13716, P14618 | ALAD, PKM2 | More | | Olmesartan | hsa01524 | Platinum drug resistance | 1.13E-02 | 5 | P10415, Q13489, P78417, P23025, P43246 | BCL2, BIRC3, GSTO1, XPA, MSH2 | More | | Olmesartan | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | | Olmesartan | hsa03008 | Ribosome biogenesis in eukaryotes | 2.60E-03 | 5 | Q9NYH9, P78345, Q9BVP2, O15381, Q9GZY0 | UTP6, RPP38, GNL3, NVL, NXF2; NXF2B | More | | Olmesartan | hsa03010 | Ribosome | 5.85E-04 | 8 | P62753, P25398, P32969, P46776, P62899, P18077, P61927, P36578 | RPS6, RPS12, RPL9, RPL27A, RPL31, RPL35A, RPL37, RPL4 | More | | Olmesartan | hsa03013 | RNA transport | 2.78E-05 | 17 | O14980, P52298, Q09161, O14893, P61326, Q15287, Q7Z3B4, P35658, P68104, Q14152, O15371, O75822, P78345, P11940, Q14240, Q9Y6A5, P51114 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, RNPS1, NUP54, NUP214, EEF1A1, EIF3A, EIF3D, EIF3J, RPP38, PABPC1, EIF4A2, TACC3, FXR1 | More | | Olmesartan | hsa03020 | RNA polymerase | 2.86E-05 | 4 | P24928, P62487, Q9GZM3, P52435 | POLR2A, POLR2G, POLR2J2, POLR2J | More | | Olmesartan | hsa03040 | Spliceosome | 3.10E-07 | 16 | Q14562, O43143, O60508, Q99633, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, Q9UMS4, P11142, Q9Y2W2, O43447, O75643 | DHX8, DHX15, CDC40, PRPF18, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, PRPF19, HSPA8, WBP11, PPIH, ASCC3L1 | More | | Olmesartan | hsa03050 | Proteasome | 3.05E-02 | 1 | P55036 | PSMD4 | More | | Olmesartan | hsa03060 | Protein export | 3.28E-02 | 2 | Q15070, O76094 | OXA1L, SRP72 | More | | Olmesartan | hsa03410 | Base excision repair | 7.59E-03 | 1 | P27695 | APEX1 | More | | Olmesartan | hsa04014 | Ras signaling pathway | 2.36E-02 | 8 | P42338, P20827, P49767, Q13009, Q7LDG7, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, TIAM1, RASGRP2, GNG5, GNG10, PLCG1 | More | | Olmesartan | hsa04015 | Rap1 signaling pathway | 9.35E-04 | 12 | P20827, P49767, P63261, Q96FS4, P11215, P25116, Q13009, Q7LDG7, P42338, P0DP23, P17252, P19174 | EFNA1, VEGFC, ACTG1, SIPA1, ITGAM, F2R, TIAM1, RASGRP2, PIK3CB, CALM1, PRKCA, PLCG1 | More | | Olmesartan | hsa04020 | Calcium signaling pathway | 1.16E-03 | 7 | Q16566, P17252, O15399, P25116, P0DP23, P23634, P49767 | CAMK4, PRKCA, GRIN2D, F2R, CALM1, ATP2B4, VEGFC | More | | Olmesartan | hsa04022 | cGMP-PKG signaling pathway | 2.55E-02 | 4 | P18848, Q8WYR1, P05141, P0DP24 | ATF4, PIK3R5, SLC25A5, CALM2 | More | | Olmesartan | hsa04024 | cAMP signaling pathway | 2.84E-02 | 5 | P0DP23, P23634, Q16566, O15399, P25116 | CALM1, ATP2B4, CAMK4, GRIN2D, F2R | More | | Olmesartan | hsa04060 | Cytokine-cytokine receptor interaction | 1.77E-05 | 20 | P27930, P14778, P08476, P26842, Q9UHF4, Q13651, P16871, Q9HBE5, P25024, Q9UBD3, P47992, P02775, P01375, P09341, P32248, P51684, P18510, P09603, P01730, Q93038 | IL1R2, IL1R1, INHBA, CD27, IL20RA, IL10RA, IL7R, IL21R, CXCR1, XCL2, XCL1, PPBP, TNF, CXCL1, CCR7, CCR6, IL1RN, CSF1, CD4, TNFRSF25 | More | | Olmesartan | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 3.45E-06 | 13 | P51684, P32248, P09341, P19875, P25024, P02775, P25025, P47992, Q9UBD3, Q13651, P14784, Q9UHF4, P01375 | CCR6, CCR7, CXCL1, CXCL2, CXCR1, PPBP, CXCR2, XCL1, XCL2, IL10RA, IL2RB, IL20RA, TNF | More | | Olmesartan | hsa04062 | Chemokine signaling pathway | 9.51E-06 | 19 | P25024, P25025, P09341, P19875, P47992, Q9UBD3, P09769, P07948, P42338, P19174, P63218, P50151, P43250, P49407, Q08881, Q7LDG7, Q13009, P49841, Q8WYR1 | CXCR1, CXCR2, CXCL1, CXCL2, XCL1, XCL2, FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, ARRB1, ITK, RASGRP2, TIAM1, GSK3B, PIK3R5 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q13547 | HDAC1 | Histone deacetylase 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | -0.803 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | 1 | Q13547 | HDAC1 | Histone deacetylase 1 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | -0.719 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.929 | Q13547 | HDAC1 | Histone deacetylase 1 | P09341 | CXCL1 | Growth-regulated alpha protein | -0.736 | Q13547 | HDAC1 | Histone deacetylase 1 | P19875 | CXCL2 | C-X-C motif chemokine 2 | -0.862 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P47992 | XCL1 | Lymphotactin | -0.706 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q9UBD3 | XCL2 | Cytokine SCM-1 beta | -0.706 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P09769 | FGR | Tyrosine-protein kinase Fgr | 0.796 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.971 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.707 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | Q13547 | HDAC1 | Histone deacetylase 1 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | -0.864 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.727 | Q13547 | HDAC1 | Histone deacetylase 1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.716 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.743 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43250 | GRK6 | G protein-coupled receptor kinase 6 | 0.818 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49407 | ARRB1 | Beta-arrestin-1 | -0.721 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13009 | TIAM1 | Rho guanine nucleotide exchange factor TIAM1 | 0.706 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q8WYR1 | PIK3R5 | Phosphoinositide 3-kinase regulatory subunit 5 | 0.752 |
| Olmesartan | hsa04064 | NF-kappa B signaling pathway | 6.15E-06 | 18 | P10415, P51617, O00463, Q13546, P14778, P01375, P19174, Q04759, Q9UDY8, Q13077, Q16548, P06239, Q8WV28, Q13315, P24522, P09341, P19875, Q06643 | BCL2, IRAK1, TRAF5, RIPK1, IL1R1, TNF, PLCG1, PRKCQ, MALT1, TRAF1, BCL2A1, LCK, BLNK, ATM, GADD45A, CXCL1, CXCL2, LTB | More | | Olmesartan | hsa04066 | HIF-1 signaling pathway | 3.40E-02 | 3 | Q09472, P07195, P10415 | EP300, LDHB, BCL2 | More | | Olmesartan | hsa04068 | FoxO signaling pathway | 3.52E-02 | 1 | Q96BR1 | SGK3 | More | | Olmesartan | hsa04070 | Phosphatidylinositol signaling system | 4.07E-02 | 4 | P0DP23, Q14643, O14732, P17252 | CALM1, ITPR1, IMPA2, PRKCA | More | | Olmesartan | hsa04071 | Sphingolipid signaling pathway | 1.82E-04 | 9 | P17252, Q9H228, P01375, Q13362, Q16537, Q9BX95, P04637, P10415, Q9UQC2 | PRKCA, EDG8, TNF, PPP2R5C, PPP2R5E, SGPP1, TP53, BCL2, GAB2 | More | | Olmesartan | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | Olmesartan | hsa04080 | Neuroactive ligand-receptor interaction | 1.20E-02 | 8 | P08311, Q15722, Q9H228, P43657, P21462, P21730, P14416, P35318 | CTSG, LTB4R, EDG8, P2RY5, FPR1, C5AR1, DRD2, ADM | More | | Olmesartan | hsa04110 | Cell cycle | 2.06E-02 | 6 | Q9UJX4, O60566, Q09472, P24522, P04637, P49918 | ANAPC5, BUB1B, EP300, GADD45A, TP53, CDKN1C | More | | Olmesartan | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Olmesartan | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Olmesartan | hsa04141 | Protein processing in endoplasmic reticulum | 8.43E-03 | 5 | P18848, Q12933, Q15436, Q99941, P07900 | ATF4, TRAF2, SEC23A, CREBL1, HSP90AA1 | More | | Olmesartan | hsa04145 | Phagosome | 1.86E-02 | 5 | P63261, Q15080, Q13509, P68371, P27824 | ACTG1, NCF4, TUBB3, TUBB2C, CANX | More | | Olmesartan | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | | Olmesartan | hsa04151 | PI3K-Akt signaling pathway | 3.53E-05 | 22 | P62753, P42338, P43657, O43521, P27348, P20827, P49767, P07900, P08238, Q8WYR1, P63218, P50151, O15335, Q16363, Q13751, P22105, P14784, Q99941, P18848, O00141, Q6ZUJ8, P30281 | RPS6, PIK3CB, P2RY5, BCL2L11, YWHAQ, EFNA1, VEGFC, HSP90AA1, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMA4, LAMB3, TNXB, IL2RB, CREBL1, ATF4, SGK, PIK3AP1, CCND3 | More | | Olmesartan | hsa04210 | Apoptosis | 3.78E-05 | 14 | P04637, P10415, O76075, P01375, Q9NR28, O75460, P24522, Q16548, Q13077, O43521, P43234, Q9UBR2, P18848, Q14643 | TP53, BCL2, DFFB, TNF, DIABLO, ERN1, GADD45A, BCL2A1, TRAF1, BCL2L11, CTSO, CTSZ, ATF4, ITPR1 | More | | Olmesartan | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | Olmesartan | hsa04217 | Necroptosis | 2.04E-05 | 12 | P01375, Q12933, P48023, Q14765, P07900, P15104, P05141, P01584, P0C0S5, Q99878, Q13557, Q9H444 | TNF, TRAF2, FASLG, STAT4, HSP90AA1, GLUL, SLC25A5, IL1B, H2AFZ, H2AC14, CAMK2D, CHMP4B | More | | Olmesartan | hsa04261 | Adrenergic signaling in cardiomyocytes | 3.44E-02 | 5 | Q16537, P0DP23, P17252, P10415, P20020 | PPP2R5E, CALM1, PRKCA, BCL2, ATP2B1 | More | | Olmesartan | hsa04270 | Vascular smooth muscle contraction | 2.89E-02 | 2 | P35579, P35318 | MYH9, ADM | More | | Olmesartan | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | | Olmesartan | hsa04350 | TGF-beta signaling pathway | 4.88E-02 | 1 | P37173 | TGFBR2 | More | | Olmesartan | hsa04360 | Axon guidance | 4.04E-02 | 6 | P16333, P20827, O95631, P42338, P07332, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, PLCG1 | More | | Olmesartan | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Olmesartan | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | | Olmesartan | hsa04390 | Hippo signaling pathway | 1.47E-02 | 5 | P63261, Q13485, Q9UJU2, O43623, Q13489 | ACTG1, SMAD4, LEF1, SNAI2, BIRC3 | More | | Olmesartan | hsa04510 | Focal adhesion | 3.21E-02 | 6 | Q15942, P17252, Q13489, P10415, P49767, P63261 | ZYX, PRKCA, BIRC3, BCL2, VEGFC, ACTG1 | More | | Olmesartan | hsa04512 | ECM-receptor interaction | 1.90E-02 | 2 | P26012, P16070 | ITGB8, CD44 | More | | Olmesartan | hsa04520 | Adherens junction | 3.36E-02 | 4 | Q13485, Q9UJU2, O43623, P63261 | SMAD4, LEF1, SNAI2, ACTG1 | More | | Olmesartan | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Olmesartan | hsa04540 | Gap junction | 4.76E-02 | 3 | P17252, Q13509, P68371 | PRKCA, TUBB3, TUBB2C | More | | Olmesartan | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | | Olmesartan | hsa04612 | Antigen processing and presentation | 2.05E-05 | 8 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Olmesartan | hsa04613 | Neutrophil extracellular trap formation | 8.63E-06 | 22 | P17252, P11215, O60603, P05164, P08246, Q9UM07, Q13547, Q92769, Q6FI13, Q93077, P62807, P33778, O60814, P68431, P14598, Q15080, P08311, O75015, P21730, P21462, O43315, Q16539 | PRKCA, ITGAM, TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC3, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Olmesartan | hsa04614 | Renin-angiotensin system | 1.52E-02 | 1 | P50052 | AGTR2 | More | | Olmesartan | hsa04621 | NOD-like receptor signaling pathway | 3.15E-02 | 10 | Q16539, Q14643, P21796, P10599, Q9H1Y0, P43490, O00463, P01375, P09341, P12838 | MAPK14, ITPR1, VDAC1, TXN, ATG5, PBEF1, TRAF5, TNF, CXCL1, DEFA4 | More | | Olmesartan | hsa04640 | Hematopoietic cell lineage | 5.47E-05 | 13 | P13612, P14778, P27930, P11215, P25063, P07766, P09693, P01732, P01730, P09564, P13765, P01375, P09603 | ITGA4, IL1R1, IL1R2, ITGAM, CD24, CD3E, CD3G, CD8A, CD4, CD7, HLA-DOB, TNF, CSF1 | More | | Olmesartan | hsa04650 | Natural killer cell mediated cytotoxicity | 9.07E-13 | 16 | P16298, P50591, P19174, P01375, P78314, P06239, O60880, P20963, P42338, Q02750, Q13241, P26718, O14931, O75015, P26717, P26715 | PPP3CB, TNFSF10, PLCG1, TNF, SH3BP2, LCK, SH2D1A, CD247, PIK3CB, MAP2K1, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P11511 | CYP19A1 | Aromatase | P16298 | PPP3CB | Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform | 0.706 | P11511 | CYP19A1 | Aromatase | P50591 | TNFSF10 | Tumor necrosis factor ligand superfamily member 10 | 0.701 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P01375 | TNF | Tumor necrosis factor | 0.761 | O75475 | PSIP1 | PC4 and SFRS1-interacting protein | P01375 | TNF | Tumor necrosis factor | -0.72 | P08311 | CTSG | Cathepsin G | P01375 | TNF | Tumor necrosis factor | 0.733 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | O75475 | PSIP1 | PC4 and SFRS1-interacting protein | P78314 | SH3BP2 | SH3 domain-binding protein 2 | -0.731 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.748 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P08311 | CTSG | Cathepsin G | P06239 | LCK | Tyrosine-protein kinase Lck | -0.816 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.786 | O75475 | PSIP1 | PC4 and SFRS1-interacting protein | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.734 | Q13547 | HDAC1 | Histone deacetylase 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.786 | P08311 | CTSG | Cathepsin G | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.92 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.751 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.707 | O75475 | PSIP1 | PC4 and SFRS1-interacting protein | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.734 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P08311 | CTSG | Cathepsin G | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.888 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | P11511 | CYP19A1 | Aromatase | Q02750 | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 0.783 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.719 | O75475 | PSIP1 | PC4 and SFRS1-interacting protein | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.772 | Q13547 | HDAC1 | Histone deacetylase 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.807 | P08311 | CTSG | Cathepsin G | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.812 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.773 | O75475 | PSIP1 | PC4 and SFRS1-interacting protein | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.83 | Q13547 | HDAC1 | Histone deacetylase 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.772 | P08311 | CTSG | Cathepsin G | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.875 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.842 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | Q13547 | HDAC1 | Histone deacetylase 1 | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.735 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.892 | O75475 | PSIP1 | PC4 and SFRS1-interacting protein | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | -0.879 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.913 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | O75475 | PSIP1 | PC4 and SFRS1-interacting protein | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.783 | P08311 | CTSG | Cathepsin G | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.867 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 | O75475 | PSIP1 | PC4 and SFRS1-interacting protein | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.783 | P08311 | CTSG | Cathepsin G | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.867 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 |
| Olmesartan | hsa04657 | IL-17 signaling pathway | 2.28E-06 | 9 | P07900, O00463, Q12933, Q16539, P49841, P09341, P14780, P80188, P01375 | HSP90AA1, TRAF5, TRAF2, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF | More | | Olmesartan | hsa04658 | Th1 and Th2 cell differentiation | 2.31E-08 | 13 | Q04759, P07766, P20963, P09693, P19174, P01730, P06239, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, PLCG1, CD4, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | Olmesartan | hsa04659 | Th17 cell differentiation | 6.58E-08 | 16 | Q04759, P19174, P01730, P06239, P14784, P13765, P14778, Q9HBE5, Q9UL17, P23771, P84022, Q13485, P08238, P07766, P09693, P20963 | PRKCQ, PLCG1, CD4, LCK, IL2RB, HLA-DOB, IL1R1, IL21R, TBX21, GATA3, SMAD3, SMAD4, HSP90AB1, CD3E, CD3G, CD247 | More | | Olmesartan | hsa04660 | T cell receptor signaling pathway | 2.06E-07 | 14 | P01375, Q04759, P42338, O95267, Q08881, P19174, P07766, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, PIK3CB, RASGRP1, ITK, PLCG1, CD3E, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Olmesartan | hsa04662 | B cell receptor signaling pathway | 1.74E-02 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Olmesartan | hsa04664 | Fc epsilon RI signaling pathway | 1.48E-03 | 6 | P42338, Q9UQC2, P07948, P19174, P09917, P20292 | PIK3CB, GAB2, LYN, PLCG1, ALOX5, ALOX5AP | More | | Olmesartan | hsa04666 | Fc gamma R-mediated phagocytosis | 2.22E-02 | 4 | P49006, P06396, P14598, P17252 | MARCKSL1, GSN, NCF1, PRKCA | More | | Olmesartan | hsa04668 | TNF signaling pathway | 1.32E-03 | 5 | Q12933, Q99941, P18848, P01584, P20333 | TRAF2, CREBL1, ATF4, IL1B, TNFRSF1B | More | | Olmesartan | hsa04720 | Long-term potentiation | 2.27E-05 | 8 | P17252, Q16566, P16298, P0DP23, P51812, O15399, Q02750, Q14643 | PRKCA, CAMK4, PPP3CB, CALM1, RPS6KA3, GRIN2D, MAP2K1, ITPR1 | More | | Olmesartan | hsa04721 | Synaptic vesicle cycle | 1.80E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | Olmesartan | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Olmesartan | hsa04724 | Glutamatergic synapse | 2.72E-03 | 5 | P48058, P43003, P63218, P50151, P15104 | GRIA4, SLC1A3, GNG5, GNG10, GLUL | More | | Olmesartan | hsa04727 | GABAergic synapse | 3.89E-02 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | | Olmesartan | hsa04728 | Dopaminergic synapse | 3.73E-03 | 9 | P14416, P63218, P50151, P49841, Q99941, P18848, Q16539, Q13557, P49407 | DRD2, GNG5, GNG10, GSK3B, CREBL1, ATF4, MAPK14, CAMK2D, ARRB1 | More | | Olmesartan | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | Olmesartan | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | Olmesartan | hsa04911 | Insulin secretion | 5.41E-03 | 3 | Q99941, P18848, Q13557 | CREBL1, ATF4, CAMK2D | More | | Olmesartan | hsa04912 | GnRH signaling pathway | 4.42E-02 | 3 | P17252, Q14643, P0DP23 | PRKCA, ITPR1, CALM1 | More | | Olmesartan | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | | Olmesartan | hsa04916 | Melanogenesis | 3.55E-02 | 3 | P0DP23, Q9UJU2, P17252 | CALM1, LEF1, PRKCA | More | | Olmesartan | hsa04918 | Thyroid hormone synthesis | 1.44E-02 | 3 | Q99941, P18848, P02768 | CREBL1, ATF4, ALB | More | | Olmesartan | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | | Olmesartan | hsa04921 | Oxytocin signaling pathway | 4.19E-02 | 4 | P0DP23, P17252, Q16566, P63261 | CALM1, PRKCA, CAMK4, ACTG1 | More | | Olmesartan | hsa04922 | Glucagon signaling pathway | 4.18E-02 | 2 | P14618, P06737 | PKM2, PYGL | More | | Olmesartan | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | Olmesartan | hsa04925 | Aldosterone synthesis and secretion | 1.83E-05 | 9 | Q14643, Q99941, P18848, P0DP23, P17252, Q16566, Q13557, P20020, P23634 | ITPR1, CREBL1, ATF4, CALM1, PRKCA, CAMK4, CAMK2D, ATP2B1, ATP2B4 | More | | Olmesartan | hsa04927 | Cortisol synthesis and secretion | 4.36E-02 | 2 | Q99941, P18848 | CREBL1, ATF4 | More | | Olmesartan | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | Olmesartan | hsa04932 | Non-alcoholic fatty liver disease | 1.38E-04 | 8 | P01375, P49841, O43521, P18848, P48023, O75460, P01584, P13073 | TNF, GSK3B, BCL2L11, ATF4, FASLG, ERN1, IL1B, COX4I1 | More | | Olmesartan | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.93E-03 | 7 | P84022, Q13485, P10415, P42338, P49767, P17252, P19174 | SMAD3, SMAD4, BCL2, PIK3CB, VEGFC, PRKCA, PLCG1 | More | | Olmesartan | hsa04934 | Cushing syndrome | 8.89E-04 | 4 | Q99941, P18848, O15169, Q13557 | CREBL1, ATF4, AXIN1, CAMK2D | More | | Olmesartan | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Olmesartan | hsa04962 | Vasopressin-regulated water reabsorption | 7.22E-03 | 2 | P52566, P62491 | ARHGDIB, RAB11A | More | | Olmesartan | hsa04964 | Proximal tubule bicarbonate reclamation | 2.74E-03 | 3 | P22748, P00918, P49448 | CA4, CA2, GLUD2 | More | | Olmesartan | hsa04966 | Collecting duct acid secretion | 2.32E-03 | 3 | P02730, P00918, Q9Y666 | SLC4A1, CA2, SLC12A7 | More | | Olmesartan | hsa04970 | Salivary secretion | 8.71E-04 | 5 | Q14643, P20020, P23634, P17252, P0DP23 | ITPR1, ATP2B1, ATP2B4, PRKCA, CALM1 | More | | Olmesartan | hsa04971 | Gastric acid secretion | 4.76E-02 | 3 | P17252, P63261, P0DP23 | PRKCA, ACTG1, CALM1 | More | | Olmesartan | hsa04972 | Pancreatic secretion | 1.00E-02 | 3 | Q14643, P20020, P17252 | ITPR1, ATP2B1, PRKCA | More | | Olmesartan | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Olmesartan | hsa04976 | Bile secretion | 2.79E-03 | 3 | O43315, P22694, P08183 | AQP9, PRKACB, ABCB1 | More | | Olmesartan | hsa04978 | Mineral absorption | 3.94E-02 | 2 | P23634, Q9BXS9 | ATP2B4, SLC26A6 | More | | Olmesartan | hsa05010 | Alzheimer disease | 2.78E-02 | 6 | P13073, O75460, P0DP24, P01584, P18848, P05141 | COX4I1, ERN1, CALM2, IL1B, ATF4, SLC25A5 | More | | Olmesartan | hsa05012 | Parkinson disease | 3.89E-02 | 5 | P13073, P05141, O75460, P18848, P0DP24 | COX4I1, SLC25A5, ERN1, ATF4, CALM2 | More | | Olmesartan | hsa05014 | Amyotrophic lateral sclerosis | 4.31E-02 | 7 | O15399, P10415, Q13509, P68371, Q53GS7, P63261, Q9GZY0 | GRIN2D, BCL2, TUBB3, TUBB2C, GLE1, ACTG1, NXF2; NXF2B | More | | Olmesartan | hsa05016 | Huntington disease | 1.46E-03 | 8 | P13073, Q9GZM3, P24928, P62487, P52435, P05141, O75460, P55036 | COX4I1, POLR2J2, POLR2A, POLR2G, POLR2J, SLC25A5, ERN1, PSMD4 | More | | Olmesartan | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.98E-02 | 7 | P13073, O75460, P18848, P05141, P20333, P01584, P0DP24 | COX4I1, ERN1, ATF4, SLC25A5, TNFRSF1B, IL1B, CALM2 | More | | Olmesartan | hsa05030 | Cocaine addiction | 4.36E-02 | 2 | Q99941, P18848 | CREBL1, ATF4 | More | | Olmesartan | hsa05031 | Amphetamine addiction | 2.40E-04 | 7 | O15399, P0DP23, Q16566, Q13557, Q99941, P18848, P17252 | GRIN2D, CALM1, CAMK4, CAMK2D, CREBL1, ATF4, PRKCA | More | | Olmesartan | hsa05034 | Alcoholism | 3.11E-05 | 6 | Q96RR4, Q93077, P62807, O60814, P84243, P68431 | CAMKK2, HIST1H2AC, HIST1H2BC, H2BC12, H3F3A, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Olmesartan | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.22E-06 | 7 | Q16539, P09341, P19875, P19174, P25024, P25025, P07948 | MAPK14, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2, LYN | More | | Olmesartan | hsa05132 | Salmonella infection | 2.12E-04 | 13 | P51617, Q9UJU2, P63261, Q13546, Q13489, P10415, O75369, O60603, Q9BQS8, P51808, Q13561, Q13509, P68371 | IRAK1, LEF1, ACTG1, RIPK1, BIRC3, BCL2, FLNB, TLR2, FYCO1, DYNLT3, DCTN2, TUBB3, TUBB2C | More | | Olmesartan | hsa05133 | Pertussis | 3.10E-03 | 4 | P0DP23, P23528, P09871, P0C0L4 | CALM1, CFL1, C1S, C4A | More | | Olmesartan | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | Olmesartan | hsa05135 | Yersinia infection | 4.65E-02 | 5 | P13612, P06239, Q16539, P01375, P49841 | ITGA4, LCK, MAPK14, TNF, GSK3B | More | | Olmesartan | hsa05140 | Leishmaniasis | 3.53E-06 | 11 | O75015, P14598, P13765, O60603, P25963, P01375, P29350, P49006, Q16539, P51617, Q15080 | FCGR3B, NCF1, HLA-DOB, TLR2, NFKBIA, TNF, PTPN6, MARCKSL1, MAPK14, IRAK1, NCF4 | More | | Olmesartan | hsa05143 | African trypanosomiasis | 7.50E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | | Olmesartan | hsa05144 | Malaria | 1.65E-05 | 7 | P60033, P69905, P68871, O60603, P01375, P35443, P26718 | CD81, HBA2, HBB, TLR2, TNF, THBS4, KLRK1 | More | | Olmesartan | hsa05146 | Amoebiasis | 1.61E-10 | 13 | Q13751, P09341, P19875, P14778, P27930, P01375, O60603, P42338, P11215, P05089, P22694, P12814, P08311 | LAMB3, CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, PIK3CB, ITGAM, ARG1, PRKACB, ACTN1, CTSG | More | | Olmesartan | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Olmesartan | hsa05161 | Hepatitis B | 2.86E-02 | 3 | Q99941, P18848, P27348 | CREBL1, ATF4, YWHAQ | More | | Olmesartan | hsa05163 | Human cytomegalovirus infection | 2.76E-04 | 10 | P01375, P63218, P50151, Q14643, P49841, P14778, P25025, Q16539, P04637, O00463 | TNF, GNG5, GNG10, ITPR1, GSK3B, IL1R1, CXCR2, MAPK14, TP53, TRAF5 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
O75475 | PSIP1 | PC4 and SFRS1-interacting protein | P01375 | TNF | Tumor necrosis factor | -0.72 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | O75475 | PSIP1 | PC4 and SFRS1-interacting protein | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | -0.701 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.727 | O75475 | PSIP1 | PC4 and SFRS1-interacting protein | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.721 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.743 | O75475 | PSIP1 | PC4 and SFRS1-interacting protein | Q14643 | ITPR1 | Inositol 1,4,5-trisphosphate receptor type 1 | 0.723 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q14643 | ITPR1 | Inositol 1,4,5-trisphosphate receptor type 1 | -0.728 | O75475 | PSIP1 | PC4 and SFRS1-interacting protein | P49841 | GSK3B | Glycogen synthase kinase-3 beta | -0.742 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.78 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 | O75475 | PSIP1 | PC4 and SFRS1-interacting protein | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.778 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.857 | O75475 | PSIP1 | PC4 and SFRS1-interacting protein | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | -0.903 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.889 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.929 | O75475 | PSIP1 | PC4 and SFRS1-interacting protein | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | -0.875 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.795 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P04637 | TP53 | Cellular tumor antigen p53 | -0.823 | O75475 | PSIP1 | PC4 and SFRS1-interacting protein | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.842 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.788 |
| Olmesartan | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | | Olmesartan | hsa05168 | Herpes simplex virus 1 infection | 1.94E-02 | 9 | Q9UKJ0, P01568, Q9GZY0, Q01130, Q13489, Q13398, Q03923, Q9UDV6, P10415 | PILRB, IFNA21, NXF2; NXF2B, SFRS2, BIRC3, ZNF211, ZNF85, ZNF212, BCL2 | More | | Olmesartan | hsa05169 | Epstein-Barr virus infection | 2.15E-03 | 10 | P13765, Q92769, P04637, Q13546, P10415, P24522, O60603, P29728, P51617, P09693 | HLA-DOB, HDAC2, TP53, RIPK1, BCL2, GADD45A, TLR2, OAS2, IRAK1, CD3G | More | | Olmesartan | hsa05170 | Human immunodeficiency virus 1 infection | 1.24E-04 | 14 | Q02750, P62879, P16298, P0DP23, Q05397, P17252, Q13546, Q14643, P51617, O60603, P09693, P10415, Q9Y6Q5, P20333 | MAP2K1, GNB2, PPP3CB, CALM1, PTK2, PRKCA, RIPK1, ITPR1, IRAK1, TLR2, CD3G, BCL2, AP1M2, TNFRSF1B | More | | Olmesartan | hsa05171 | Coronavirus disease - COVID-19 | 1.51E-03 | 8 | P62753, P25398, P36578, P32969, P46776, P62899, P18077, P61927 | RPS6, RPS12, RPL4, RPL9, RPL27A, RPL31, RPL35A, RPL37 | More | | Olmesartan | hsa05200 | Pathways in cancer | 9.22E-05 | 32 | Q13751, P42338, P08238, P19174, P04637, Q9UJU2, P17252, Q09472, P43246, P84022, Q13485, Q13547, P14923, P30281, P10415, Q13489, Q13077, P49767, P43657, P25116, P63218, P50151, Q14344, O95267, Q7LDG7, P78417, P24522, O75293, P0DP23, P01568, P14784, P16871 | LAMB3, PIK3CB, HSP90AB1, PLCG1, TP53, LEF1, PRKCA, EP300, MSH2, SMAD3, SMAD4, HDAC1, JUP, CCND3, BCL2, BIRC3, TRAF1, VEGFC, P2RY5, F2R, GNG5, GNG10, GNA13, RASGRP1, RASGRP2, GSTO1, GADD45A, GADD45B, CALM1, IFNA21, IL2RB, IL7R | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13751 | LAMB3 | Laminin subunit beta-3 | 0.844 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | P32248 | CCR7 | C-C chemokine receptor type 7 | P04637 | TP53 | Cellular tumor antigen p53 | 0.77 | P46091 | GPR1 | Chemerin-like receptor 2 | Q9UJU2 | LEF1 | Lymphoid enhancer-binding factor 1 | 0.736 | P32248 | CCR7 | C-C chemokine receptor type 7 | Q9UJU2 | LEF1 | Lymphoid enhancer-binding factor 1 | 0.813 | P46091 | GPR1 | Chemerin-like receptor 2 | P17252 | PRKCA | Protein kinase C alpha type | 0.741 | P32248 | CCR7 | C-C chemokine receptor type 7 | Q09472 | EP300 | Histone acetyltransferase p300 | -0.791 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.811 | P46091 | GPR1 | Chemerin-like receptor 2 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.838 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | P46091 | GPR1 | Chemerin-like receptor 2 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.809 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.754 | P46091 | GPR1 | Chemerin-like receptor 2 | P14923 | JUP | Junction plakoglobin | 0.883 | P32248 | CCR7 | C-C chemokine receptor type 7 | P14923 | JUP | Junction plakoglobin | 0.711 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P30281 | CCND3 | G1/S-specific cyclin-D3 | 0.743 | P46091 | GPR1 | Chemerin-like receptor 2 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.808 | P32248 | CCR7 | C-C chemokine receptor type 7 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.748 | P46091 | GPR1 | Chemerin-like receptor 2 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.759 | P32248 | CCR7 | C-C chemokine receptor type 7 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | 0.748 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P49767 | VEGFC | Vascular endothelial growth factor C | 0.743 | P46091 | GPR1 | Chemerin-like receptor 2 | P49767 | VEGFC | Vascular endothelial growth factor C | 0.718 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | -0.735 | P46091 | GPR1 | Chemerin-like receptor 2 | P25116 | F2R | Proteinase-activated receptor 1 | 0.76 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | 0.87 | P32248 | CCR7 | C-C chemokine receptor type 7 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | 0.792 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | P46091 | GPR1 | Chemerin-like receptor 2 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | 0.738 | P32248 | CCR7 | C-C chemokine receptor type 7 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.862 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | 0.731 | P46091 | GPR1 | Chemerin-like receptor 2 | P0DP23 | CALM1 | Calmodulin-1 | -0.846 | P46091 | GPR1 | Chemerin-like receptor 2 | P01568 | IFNA21 | Interferon alpha-21 | 0.724 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 | P32248 | CCR7 | C-C chemokine receptor type 7 | P16871 | IL7R | Interleukin-7 receptor subunit alpha | 0.743 |
| Olmesartan | hsa05202 | Transcriptional misregulation in cancer | 4.22E-04 | 15 | Q15532, Q13315, P14780, P27930, P14923, Q15744, Q16548, Q13077, O15550, P04637, P05164, P12838, P08246, Q9C0K0, P24522 | SS18, ATM, MMP9, IL1R2, JUP, CEBPE, BCL2A1, TRAF1, UTX, TP53, MPO, DEFA4, ELA2, BCL11B, GADD45A | More | | Olmesartan | hsa05203 | Viral carcinogenesis | 1.62E-04 | 7 | Q12933, Q99941, P18848, P27348, Q15283, P62807, O60814 | TRAF2, CREBL1, ATF4, YWHAQ, RASA2, HIST1H2BC, H2BC12 | More | | Olmesartan | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Olmesartan | hsa05210 | Colorectal cancer | 2.41E-02 | 4 | P10415, P04637, Q9UJU2, P24522 | BCL2, TP53, LEF1, GADD45A | More | | Olmesartan | hsa05212 | Pancreatic cancer | 9.39E-03 | 5 | P42338, P37173, P84022, Q13485, O75293 | PIK3CB, TGFBR2, SMAD3, SMAD4, GADD45B | More | | Olmesartan | hsa05213 | Endometrial cancer | 1.53E-03 | 5 | O15169, Q9UJU2, Q02750, P04637, P24522 | AXIN1, LEF1, MAP2K1, TP53, GADD45A | More | | Olmesartan | hsa05214 | Glioma | 8.71E-04 | 5 | P0DP23, Q16566, P17252, P04637, P24522 | CALM1, CAMK4, PRKCA, TP53, GADD45A | More | | Olmesartan | hsa05215 | Prostate cancer | 1.94E-02 | 4 | P10415, Q9UJU2, Q09472, P04637 | BCL2, LEF1, EP300, TP53 | More | | Olmesartan | hsa05216 | Thyroid cancer | 2.42E-04 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Olmesartan | hsa05217 | Basal cell carcinoma | 1.56E-03 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Olmesartan | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | Olmesartan | hsa05220 | Chronic myeloid leukemia | 2.16E-02 | 5 | Q13547, Q13485, P84022, P42338, O75293 | HDAC1, SMAD4, SMAD3, PIK3CB, GADD45B | More | | Olmesartan | hsa05222 | Small cell lung cancer | 1.94E-02 | 4 | P10415, Q13077, P04637, P24522 | BCL2, TRAF1, TP53, GADD45A | More | | Olmesartan | hsa05224 | Breast cancer | 5.34E-03 | 5 | Q9UJU2, P49841, Q92837, P04637, P24522 | LEF1, GSK3B, FRAT1, TP53, GADD45A | More | | Olmesartan | hsa05226 | Gastric cancer | 7.13E-04 | 7 | Q02750, Q9UJU2, O15169, P04637, P24522, P14923, P10415 | MAP2K1, LEF1, AXIN1, TP53, GADD45A, JUP, BCL2 | More | | Olmesartan | hsa05230 | Central carbon metabolism in cancer | 4.04E-02 | 2 | P07195, P04637 | LDHB, TP53 | More | | Olmesartan | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.56E-04 | 11 | P42338, O95267, P19174, P07766, P20963, P09693, P06239, O60603, Q04759, Q16539, P01730 | PIK3CB, RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, TLR2, PRKCQ, MAPK14, CD4 | More | | Olmesartan | hsa05310 | Asthma | 3.20E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Olmesartan | hsa05321 | Inflammatory bowel disease | 1.25E-03 | 6 | P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | | Olmesartan | hsa05322 | Systemic lupus erythematosus | 1.20E-05 | 11 | P08246, P08311, P09871, P01375, P13765, Q93077, P62807, Q16778, O60814, P68431, P12814 | ELA2, CTSG, C1S, TNF, HLA-DOB, HIST1H2AC, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, ACTN1 | More | | Olmesartan | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Olmesartan | hsa05332 | Graft-versus-host disease | 2.41E-03 | 5 | P13765, P48023, P01375, P26715, Q13241 | HLA-DOB, FASLG, TNF, KLRC1, KLRD1 | More | | Olmesartan | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | | Olmesartan | hsa05418 | Fluid shear stress and atherosclerosis | 3.35E-05 | 12 | Q16539, P78417, P10599, P14780, P01375, P63261, P04637, P10415, P14778, P27930, P0DP23, Q92974 | MAPK14, GSTO1, TXN, MMP9, TNF, ACTG1, TP53, BCL2, IL1R1, IL1R2, CALM1, ARHGEF2 | More | | |